STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
R
A
Completed
- Allergic Conjunctivitis
- Reproxalap Ophthalmic Solution (0.25%)
- +2 more
- Houston, TexasSlade & Baker Vision
2020-12-02
Dec 2, 2020B
Recruiting
- Myopia
- Atropine 0.1% Ophthalmic Solution
- +2 more
- Birmingham, Alabama
- +18 more
2021-12-14
Dec 14, 2021R
Active, not recruiting
- Dry Eye Syndromes
- Dry Eye
- RGN-259
- Placebo
- Phoenix, Arizona
- +19 more
2021-11-01
Nov 1, 2021E
Completed
- Presbyopia
- Pilocarpine Ophthalmic
- Placebo
- Azusa, California
- +8 more
2021-08-05
Aug 5, 2021A
Completed
- Conjunctivitis, Allergic
- Reproxalap Ophthalmic Solution (0.25%)
- +2 more
- Mississauga, Ontario, CanadaInflamax Research Limited
2020-05-11
May 11, 2020M
Completed
- Keratoconjunctivitis Sicca
- Dry Eye
- tavilermide ophthalmic solution
- Placebo
- Phoenix, Arizona
- +21 more
2021-10-18
Oct 18, 2021R
R
Terminated
- Neurotrophic Keratopathy
- RGN-259
- Placebo
- Lancaster, California
- +10 more
2020-06-30
Jun 30, 2020A
Completed
- Allergic Conjunctivitis
- Reproxalap Ophthalmic Solution (0.25%)
- +2 more
- Phoenix, Arizona
- +6 more
2019-10-30
Oct 30, 2019M
Completed
- Dry Eye
- MIM-D3 Ophthalmic Solution
- Placebo Ophthalmic Solution
- Andover, MassachusettsOra, Inc.
2019-08-15
Aug 15, 2019A
Completed
- Glaucoma
- fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5% ophthalmic solution
- fixed combination of dorzolamide hydrochloride timolol maleate ophthalmic solution
- Indianapolis, Indiana(unnamed)
2019-04-10
Apr 10, 2019A
Completed
- Inflammation Eye
- Bromfenac 0.09 % Ophthalmic Solution
- Dexamethasone 0.1% ophthalmic suspension
- Reggio Emilia, RE, ItalyArcispedale Santa Maria Nuova IRCSS - Ophthalmology
2019-05-31
May 31, 2019O
Completed
- Graft Versus Host Disease
- +7 more
- Brimonidine Tartrate
- Placebos
- Phoenix, Arizona
- +12 more
2020-06-30
Jun 30, 2020J
Completed
- Ophthalmic Solutions
- F# 13418-148 Eye Drops
- +2 more
- Andover, MassachusettsAndover Eye Associates
2018-08-24
Aug 24, 2018O
Not yet recruiting
- Open Angle Glaucoma
- ONL1204 Ophthalmic solution (Dose A)
- +2 more
- Albury, New South Wales, Australia
- +1 more
2021-12-06
Dec 6, 2021A
Recruiting
- Dry Eye
- Reproxalap Ophthalmic Solution (0.25%)
- Xiidra® (5% lifitegrast ophthalmic solution)
- Mississauga, Ontario, CanadaCliantha Research
2022-01-12
Jan 12, 2022A
Completed
- Primary Open Angle Glaucoma
- Ocular Hypertension
- Netarsudil ophthalmic solution 0.02%
- Ripasudil hydrochloride hydrate ophthalmic solution 0.4%
- Setagaya-Ku, Tokyo, JapanSeijo Clinic
2021-08-29
Aug 29, 2021A
Recruiting
- Dry Eye Disease
- Reproxalap Ophthalmic Solution (0.25%)
- Placebo Comparator
- Andover, MassachusettsAndover Eye Associates
2022-02-08
Feb 8, 2022A
Recruiting
- Allergic Conjunctivitis
- Reproxalap Ophthalmic Solution (0.25%)
- Vehicle Ophthalmic Solution
- Mississauga, Ontario, CanadaCliantha Research
2022-02-09
Feb 9, 2022A
Completed
- Dry Eye
- Dry Eye Syndromes
- Reproxalap Ophthalmic Solution (0.25%)
- Vehicle Opthalmic Solution
- Memphis, TennesseeUniversity Clinical Health
2022-03-28
Mar 28, 2022A
Completed
- Dry Eye
- Reproxalap Ophthalmic Solution (0.25%)
- Vehicle Ophthalmic Solution
- Andover, MassachusettsAndover Eye Associates
2021-12-08
Dec 8, 2021F
Completed
- Allergic Conjunctivitis
- Bilastine Ophthalmic Solution 0.6%
- +2 more
- Phoenix, Arizona
- +5 more
2021-11-16
Nov 16, 2021A
Recruiting
- Dry Eye
- Reproxalap Ophthalmic Solution (0.25%)
- Vehicle Ophthalmic Solution
- Raynham, MassachusettsAndover Eye Associates (Raynham)
2022-01-31
Jan 31, 2022V
Completed
- Dry Eye
- VVN001 Ophthalmic Solution 1%
- +2 more
- Durham, North CarolinaLexitas
2022-01-31
Jan 31, 2022